Zymeworks announced the FDA approved a Ziihera plus tislelizumab and chemotherapy regimen for first-line HER2-positive gastroesophageal adenocarcinoma, boosting its diversified collaboration strategy.
Zymeworks announced the FDA approved a Ziihera plus tislelizumab and chemotherapy regimen for first-line HER2-positive gastroesophageal adenocarcinoma, boosting its diversified collaboration strategy.